This study is testing a new treatment called autoantibody reduction therapy (AART) for people with progressive idiopathic pulmonary fibrosis (IPF). IPF is a lung disease that gets worse over time. AART involves three parts: therapeutic plasma exchange (TPE), which removes your blood plasma and replaces it; rituximab, a medication given by infusion; and intravenous immunoglobulin (IVIg), which are infusions of human antibodies. You could also receive your usual IPF medications. The study wants to see if AART is safe and effective compared to your usual care. To join, you need to be between 40 and 85 years old, have a confirmed diagnosis of IPF, and your IPF must have worsened by a certain amount in the last year. The main goal is to see how your lung function (measured by Forced Vital Capacity or FVC) changes after 180 days. The study is currently recruiting participants.

Study design

This is a Phase IIb interventional study planning to enroll 52 participants. Participants will be randomly assigned by computer to either the AART treatment or their usual care.

What's involved

You will be observed for six months, with assessments at the start, 30 days, 90 days, and 180 days after randomization.

Compensation

Not stated in the trial record.

Follow-up

Participants will be observed for 180 days after randomization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.